Personalized medicine: Predictors for the efficiency of biological agent therapy for rheumatoid arthritis
The clinical introduction of biological agents (BAs) is one of the most significant advances in rheumatology in recent decades. At the same time, the cost of this treatment is very high; the development of methods for predicting the results of proposed therapy may therefore be of great interest. A n...
Main Authors: | M. A. Kotovskaya, N. Yu. Nikishina, Yu. A. Olyunin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2017-04-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/748 |
Similar Items
-
Safety of using genetic engineering biological agents in rheumatoid arthritis
by: N V Chichasova, et al.
Published: (2010-03-01) -
USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: E L Nasonov, et al.
Published: (2010-03-01) -
Biological agents for endoprosthetic joint replacement in patients with rheumatoid arthritis
by: Viktoria Nikolaevna Khlaboshina, et al.
Published: (2014-12-01) -
A CURRENT VIEW ON THE PROBLEM OF RAPIDLY PROGRESSIVE RHEUMATOID ARTHRITIS
by: Dmitry Evgenyevich Karateyev
Published: (2010-06-01) -
TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS WITH COMBINED PATHOLOGY
by: D. I. Khusainova, et al.
Published: (2020-06-01)